PRCTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
PROCEPT BioRobotics Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$18.28+0.71 (+4.04%)
Close on Oct 19, 2026
- Market cap
- $1.04B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
63.7%+80.0 pts over 5 years
Operating margin
-33.7%+585.7 pts over 5 years
Net margin
-31.0%+656.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +37.2% | +60.1% | +109.0% | – | |
| Gross profit | +43.1% | +74.3% | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 32.5% | -24.9% | |
| Return on assets | – | – | -18.3% | |
| Current ratio | – | 7.59 | 6.85 | |
| Debt to equity | – | -0.27 | 0.14 | |
| Net debt to EBITDA | – | 1.16× | 2.41× | |
| Interest coverage | – | -9.1× | -29.0× | |
| Inventory turnover | – | – | 1.8× | |
| Capex to revenue | – | 3.0% | 3.0% | |
| Diluted shares | – | 4M | 56M |
Where the cash went
Fiscal 2021 to 2025, five years combined
PROCEPT BioRobotics generated $393.92M from operations and spent $42.22M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$393.92M
Used
$42.22M
Capital expenditure$42.22M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-31.0%
×Asset turnover0.59×
×Equity multiplier1.36×
=Return on equity, FY2025-24.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -31.0% | 0.59× | 1.36× | -24.9% |
| FY2024 | -40.7% | 0.48× | 1.37× | -26.8% |
| FY2023 | -77.8% | 0.38× | 1.49× | -44.3% |
| FY2022 | -116.2% | 0.23× | 1.39× | -37.6% |
| FY2021 | -173.6% | 0.15× | 5.50× | -142.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$95.57M
- Cash generatingOperating cash flow above zero-$48.99M
- Return on assets improvedROA up on the prior year-22.6% → -17.9%
- Earnings backed by cashOperating cash flow above net income-$48.99M vs -$95.57M
- Less leverageLong-term debt to assets fell9.6% → 10.2%
- Better liquidityCurrent ratio rose9.07 → 6.85
- No dilutionShare count did not rise52M → 56M
- Gross margin improvedGross margin up on the prior year61.07% → 63.70%
- More efficientAsset turnover rose0.55 → 0.58